drugset / Trial / NCT00695370
Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children
Non-randomizedOpen-labelTreatment
Summary
Hypothesis: pegfilgrastim at 300 µg/kg in hematological steady state provides an efficient stem cell mobilization in children with malignancies Design: phase 2 study. Judgment criterion: percentage of children achieving at least 5x10e6 CD34 cells with a standard apheresis (less than 2 blood volume processed)
Timeline
- Start
- 2006-01
- Primary completion
- 2007-12
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegfilgrastim | Protein / enzyme biologic | 300 ug/kg | Subcutaneous |